PHAR — Pharming Group N.V.

Summary of Pharming Group N.V. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $97.3 million, a 30% increase year-over-year.
• Operating Profit: $15.8 million, nearly four times higher than the previous year’s $4.1 million.
• Gross Profit: $90.2 million, up 33% with a gross margin of 93%, compared to 91% in Q3 2024.
• Operating Cash Flow: $32 million, restoring cash position to pre-Abliva acquisition levels.
• Year-to-Date Revenue: $269.6 million, a 32% increase, with adjusted operating profit of $29.7 million compared to a loss of $15.3 million in the same period last year.
• Cash and Marketable Securities: Increased to $168.9 million from $130.8 million at the end of Q2 2025.

2. Strategic Updates and Business Highlights

• Product Performance:
  • RUCONEST: Revenue grew by 29% to $82 million, driven by new prescribers and patient enrollments.
  • Joenja: Revenue increased by 35% to $15.1 million, with a 25% rise in patients on treatment.
• Pediatric Indication: Anticipated FDA approval for Joenja in children aged 4-11 by January 31, 2026, with 54 identified pediatric patients, one-third already on therapy.
• Pipeline Development: Ongoing studies for KL1333 in primary mitochondrial disease and a basket trial for PIDs expected to read out in late 2026.
• Cost Optimization: Significant reduction in G&A headcount to enhance capital deployment towards growth initiatives.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for 2025 to a range of $365 million to $375 million, up from $335 million to $350 million, reflecting strong performance and growth prospects.
• Operating Expenses: Expected to be between $304 million and $308 million, including nonrecurring expenses related to the Abliva acquisition.
• Long-term Vision: Pharming aims to leverage its capabilities to become a leading global rare disease company, focusing on sustainable growth and value creation.

4. Bad News, Challenges, or Points of Concern

• RUCONEST Market Withdrawal: Plans to withdraw RUCONEST from certain European markets due to unsustainable commercialization, which may impact patient access.
• Competitive Pressures: Concerns about the potential impact of new oral therapies (e.g., sebetralstat) on RUCONEST’s market share, although management believes RUCONEST serves a different patient demographic.
• VUS Patient Identification: Uncertainty around the timeline for identifying and reclassifying patients with variants of uncertain significance (VUS), with potential delays pushing some opportunities into 2026.

5. Notable Q&A Insights

• RUCONEST Competition: Management emphasized that RUCONEST serves a distinct patient population with more severe HAE, suggesting limited direct competition with new oral therapies.
• Joenja Pediatric Launch: Anticipated rapid conversion of pediatric patients already on early access to formal therapy post-approval.
• Patient Identification Strategy: Continued efforts to identify APDS patients, with a potential increase in the patient population due to new findings regarding APDS prevalence.
• Capital Allocation: Emphasis on disciplined capital allocation with no immediate plans for large M&A transactions, focusing instead on organic growth and pipeline development.

Overall, Pharming reported a strong quarter with significant revenue growth and strategic advancements, while also addressing challenges related to competition and market withdrawals.